1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Pennsylvania >
  6. Astria Acquires Quellis Biosciences

M&A Deal Summary

Astria Acquires Quellis Biosciences

On January 29, 2021, Astria acquired life science company Quellis Biosciences

Acquisition Highlights
  • This is Astria’s 1st transaction in the Life Science sector.
  • This is Astria’s 1st transaction in the United States.
  • This is Astria’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2021-01-29
Target Quellis Biosciences
Sector Life Science
Buyer(s) Astria
Deal Type Add-on Acquisition
Advisor(s) Gibson, Dunn & Crutcher (Legal)

Target

Quellis Biosciences

Philadelphia, Pennsylvania, United States
Quellis Biosciences, Inc. is a biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. Quellis Biosciences is based in Philadelphia, Pennsylvania.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Astria

Boston, Massachusetts, United States
Category Company
Founded 2008
Sector Life Science
DESCRIPTION

Astria is a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases. The company's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Its second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Astria was founded in 2008 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal